VEGFA and retinopathy of prematurity: All patients in our study were treated at or after 36 weeks of PMA and progression to tractional RD in type 1 ROP patients was similar between the treatment groups, in agreement with the study by Barry et al. The present study showing better anatomical results with less tractional RD development with anti-VEGF therapy in bigger premature infants with A-ROP indicates that these bigger A-ROP cases seem to benefit from anti-VEGF as the first choice, though this finding requires validation in broader populations.